Voclosporin: First Approval.
Drugs
; 81(5): 605-610, 2021 Apr.
Article
in English
| MEDLINE | ID: covidwho-1159706
ABSTRACT
Voclosporin (Lupkynis™) is an oral calcineurin inhibitor immunosuppressant that is being developed by Aurinia Pharmaceuticals. In January 2021, based on positive results from the pivotal phases II and III trials, oral voclosporin received its first approval in the USA for use in combination with a background immunosuppressive therapy regimen for adults with active lupus nephritis. Voclosporin is also being explored for the novel coronavirus disease 2019 (COVID-19) in kidney transplant recipients. This article summarizes the milestones in the development of voclosporin leading to this first approval for lupus nephritis.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Kidney Transplantation
/
Cyclosporine
/
Calcineurin Inhibitors
/
COVID-19 Drug Treatment
/
Immunosuppressive Agents
Topics:
Long Covid
Limits:
Animals
/
Humans
Language:
English
Journal:
Drugs
Year:
2021
Document Type:
Article
Affiliation country:
S40265-021-01488-z
Similar
MEDLINE
...
LILACS
LIS